Olanzapine/samidorphan - Alkermes
Alternative Names: ALKS 33/olanzapine; ALKS-3831; LYBALVI; Olanzapine/ALKS 33; OLZ/SAM - Alkermes plc; Samidorphan/olanzapineLatest Information Update: 25 Feb 2025
At a glance
- Originator Alkermes plc
- Class Amides; Antipsychotics; Benzodiazepines; Cyclopropanes; Mood stabilisers; Morphinans; Oxazepines; Phenanthrenes; Small molecules; Thiazepines
- Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Opioid mu receptor antagonists; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bipolar disorders; Schizophrenia
- No development reported Psychotic disorders
Most Recent Events
- 31 Jan 2025 Alkermes has patent protection for olanzapine/samidorphan in USA
- 07 Jan 2025 Olanzapine/samidorphan is still in phase III trials for Bipolar disorder (In adolescents, In children) in the USA (PO) (NCT03187769)
- 07 Jan 2025 Olanzapine/samidorphan is still in phase III trials for Bipolar disorder (In children, Treatment-experienced) in the USA (PO) (NCT05303064)